Principal Financial Group Inc. acquired a new position in shares of Theravance Biopharma, Inc. (NASDAQ:TBPH – Free Report) in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm acquired 52,264 shares of the biopharmaceutical company’s stock, valued at approximately $848,000. Principal Financial Group Inc. owned approximately 0.10% of Theravance Biopharma as of its most recent filing with the Securities & Exchange Commission.
Other institutional investors have also recently bought and sold shares of the company. Arrowstreet Capital Limited Partnership bought a new position in shares of Theravance Biopharma during the 3rd quarter worth approximately $10,611,000. Pacer Advisors Inc. bought a new stake in shares of Theravance Biopharma in the fourth quarter worth $6,342,000. Janus Henderson Group PLC boosted its holdings in Theravance Biopharma by 214.8% during the fourth quarter. Janus Henderson Group PLC now owns 400,496 shares of the biopharmaceutical company’s stock worth $7,493,000 after purchasing an additional 273,288 shares during the last quarter. Two Sigma Investments LP boosted its holdings in Theravance Biopharma by 1,199.9% during the third quarter. Two Sigma Investments LP now owns 231,272 shares of the biopharmaceutical company’s stock worth $3,377,000 after purchasing an additional 213,480 shares during the last quarter. Finally, HRT Financial LP boosted its holdings in Theravance Biopharma by 892.8% during the fourth quarter. HRT Financial LP now owns 232,852 shares of the biopharmaceutical company’s stock worth $4,356,000 after purchasing an additional 209,397 shares during the last quarter. Institutional investors own 99.10% of the company’s stock.
Theravance Biopharma Stock Performance
Shares of NASDAQ:TBPH opened at $16.86 on Friday. Theravance Biopharma, Inc. has a 52-week low of $10.82 and a 52-week high of $21.03. The company has a market capitalization of $869.13 million, a P/E ratio of 7.66 and a beta of 0.17. The company has a 50-day simple moving average of $16.71 and a 200 day simple moving average of $17.05.
Wall Street Analyst Weigh In
TBPH has been the topic of several recent research reports. BTIG Research lowered shares of Theravance Biopharma from a “buy” rating to a “neutral” rating in a research note on Monday, June 29th. Wall Street Zen cut Theravance Biopharma from a “buy” rating to a “hold” rating in a report on Saturday, May 16th. B. Riley Financial lifted their target price on Theravance Biopharma from $14.00 to $17.00 and gave the company a “neutral” rating in a research report on Tuesday, April 7th. HC Wainwright downgraded Theravance Biopharma from a “buy” rating to a “neutral” rating and lifted their target price for the company from $15.00 to $17.00 in a research report on Tuesday, July 7th. Finally, Zacks Research lowered Theravance Biopharma from a “strong-buy” rating to a “hold” rating in a report on Monday, June 8th. Eight analysts have rated the stock with a Hold rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $19.40.
View Our Latest Stock Analysis on Theravance Biopharma
Insider Activity at Theravance Biopharma
In other Theravance Biopharma news, major shareholder Eli Samaha sold 273,871 shares of the firm’s stock in a transaction on Monday, June 29th. The stock was sold at an average price of $17.23, for a total transaction of $4,718,797.33. Following the completion of the sale, the insider owned 9,237,279 shares of the company’s stock, valued at $159,158,317.17. This trade represents a 2.88% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, SVP Rhonda Farnum sold 13,314 shares of Theravance Biopharma stock in a transaction on Monday, June 15th. The stock was sold at an average price of $16.39, for a total transaction of $218,216.46. Following the transaction, the senior vice president directly owned 232,457 shares of the company’s stock, valued at approximately $3,809,970.23. This trade represents a 5.42% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 350,011 shares of company stock valued at $6,008,309 over the last quarter. 7.65% of the stock is currently owned by corporate insiders.
About Theravance Biopharma
Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.
Featured Stories
- Five stocks we like better than Theravance Biopharma
- Chevron’s Strong Quarter Shows Why It Still Leads the Energy Sector
- Amazon’s Earnings Beat Shows Why AWS Is Back at the Center of the Bull Case
- Apple’s Record Quarter Could Not Outrun Its Guidance Problem
- McKesson’s Compounding Keeps Adding Up
Want to see what other hedge funds are holding TBPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Theravance Biopharma, Inc. (NASDAQ:TBPH – Free Report).
Receive News & Ratings for Theravance Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
